Crossmark

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours

Crossref DOI link: https://doi.org/10.1136/bmjonc-2023-000249

Published Online: 2024-05-09

Published Print: 2024-05

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Naing, Aung https://orcid.org/0000-0002-4803-8513
Papadopoulos, Kyriakos P https://orcid.org/0000-0002-0667-2620
Pishvaian, Michael J

Rahma, Osama

Hanna, Glenn J

Garralda, Elena

Saavedra, Omar

Gogov, Sven

Kallender, Howard

Cheng, LuLu

Smith, Michael

Chen, Xuejun

Kuriakose, Emil

Bauer, Todd
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02903914 at ClinicalTrials.gov

Documents that mention this clinical trial

Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial
https://doi.org/10.1136/jitc-2024-010094

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours
https://doi.org/10.1136/bmjonc-2023-000249

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
https://doi.org/10.1136/jitc-2020-001356

Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127

nct02903914 at ClinicalTrials.gov

Documents that mention this clinical trial

Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial
https://doi.org/10.1136/jitc-2024-010094

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours
https://doi.org/10.1136/bmjonc-2023-000249

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
https://doi.org/10.1136/jitc-2020-001356

Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
Funding

Funding for this research was provided by:

Incyte (N/A)

Merck Sharp and Dohme United Kingdom (N/A)

Calithera Biosciences (N/A)
License Information

License valid from 2024-05-09

Document is current

Any future updates will be listed below